Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN
- First Online:
- Cite this article as:
- Custodio, A., Calles, A. & Pérez-Segura, P. Clin Transl Oncol (2010) 12: 310. doi:10.1007/s12094-010-0510-z
- 88 Downloads
Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.